{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:11:39Z","timestamp":1762459899690,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40264-020-00974-9","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T07:02:45Z","timestamp":1600066965000},"page":"1133-1140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-1538","authenticated-orcid":false,"given":"Eva Agnes Odongpiny","family":"Laker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Arinaitwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noela","family":"Owarwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annet","family":"Onzia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benson","family":"Nasasira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Wailagala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Kalule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godwin","family":"Anguzu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Kiragga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Seden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Lwanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Musomba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"unstructured":"UNAIDS. UNAIDS data 2018. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/unaids-data-2018_en.pdf. Accessed 05 Jul 2020.","key":"974_CR1"},{"unstructured":"WHO. Guidelines on the public health response to pretreatment HIV drug resistance. July 2017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255880\/9789241550055-eng.pdf;jsessionid=C3EE93B78182C3FD322531B461143CBA?sequence=1. Accessed 01 Feb 2019.","key":"974_CR2"},{"issue":"10","key":"974_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1056\/NEJMc1807653","volume":"379","author":"R Zash","year":"2018","unstructured":"Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018;379(10):979\u201381.","journal-title":"N Engl J Med."},{"unstructured":"WHO. Statement on dolutegravir. https:\/\/www.who.int\/medicines\/publications\/drugalerts\/Statement_on_DTG_18May_2018final.pdf. Accessed 01 Feb 2019.","key":"974_CR4"},{"issue":"11","key":"974_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/BF03261990","volume":"35","author":"A Dodoo","year":"2012","unstructured":"Dodoo A, Hugman B. Risk perception and communication in sub-Saharan Africa. Drug Saf. 2012;35(11):1041\u201352.","journal-title":"Drug Saf."},{"issue":"3","key":"974_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/pds.761","volume":"12","author":"WH Campbell","year":"2003","unstructured":"Campbell WH, Califf RM. Improving communication of drug risks to prevent patient injury: proceedings of a workshop. Pharmacoepidemiol Drug Saf. 2003;12(3):183\u201394.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"974_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2042098611425695","volume":"3","author":"AO Isah","year":"2012","unstructured":"Isah AO, Pal SN, Olsson S, et al. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3(1):25\u201334.","journal-title":"Ther Adv Drug Saf."},{"issue":"1","key":"974_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1472-698X-12-11","volume":"12","author":"S Nwaka","year":"2012","unstructured":"Nwaka S, Ochem A, Besson D, et al. Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent. BMC Int Health Hum Rights. 2012;12(1):11.","journal-title":"BMC Int Health Hum Rights."},{"issue":"12","key":"974_CR9","doi-asserted-by":"publisher","first-page":"e51631","DOI":"10.1371\/journal.pone.0051631","volume":"7","author":"B Castelnuovo","year":"2012","unstructured":"Castelnuovo B, Kiragga A, Afayo V, et al. Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in sub-Saharan Africa. PLoS One. 2012;7(12):e51631.","journal-title":"PLoS One."},{"unstructured":"The Antiretroviral Pregnancy Registry. http:\/\/www.apregistry.com\/. Accessed 05 Jul 2020.","key":"974_CR10"},{"issue":"11","key":"974_CR11","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1093\/jac\/dky298","volume":"73","author":"K Sweden","year":"2018","unstructured":"Sweden K, Kiiza D, Laker E, et al. High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600\u00a0mg daily. J Antimicrob Chemother. 2018;73(11):3158\u201361.","journal-title":"J Antimicrob Chemother."},{"issue":"Suppl. 1","key":"974_CR12","doi-asserted-by":"publisher","first-page":"i9","DOI":"10.1136\/qhc.0100009","volume":"10","author":"A Edwards","year":"2001","unstructured":"Edwards A, Elwyn G. Understanding risk and lessons for clinical risk communication about treatment preferences. Qual Health Care. 2001;10(Suppl. 1):i9\u201313.","journal-title":"Qual Health Care."},{"unstructured":"AfroCab. IAS2018: communique of the Kigali dolutegravir stakeholder meeting of African women living with HIV, hosted by AfroCAB. 2018, Kigali, Rwanda 13\u201314 July 2020.","key":"974_CR13"},{"key":"974_CR14","volume-title":"Building a safe house on firm ground: key findings from a global values and preferences survey regarding the sexual and reproductive health and human rights of women living with HIV","author":"S Trust","year":"2014","unstructured":"Trust S. Building a safe house on firm ground: key findings from a global values and preferences survey regarding the sexual and reproductive health and human rights of women living with HIV. Geneva: WHO; 2014."},{"issue":"1","key":"974_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/09540121.2017.1390541","volume":"30","author":"KA Thomson","year":"2018","unstructured":"Thomson KA, Dhanireddy S, Andrasik M, et al. Fertility desires and preferences for safer conception strategies among people receiving care for HIV at a publicly-funded clinic in Seattle, WA. AIDS Care. 2018;30(1):121\u20139.","journal-title":"AIDS Care."},{"issue":"5","key":"974_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/apc.2009.0293","volume":"24","author":"S Finocchario-Kessler","year":"2010","unstructured":"Finocchario-Kessler S, Dariotis JK, Sweat MD, et al. Do HIV-infected women want to discuss reproductive plans with providers, and are those conversations occurring? AIDS Patient Care STDS. 2010;24(5):317\u201323.","journal-title":"AIDS Patient Care STDS."},{"issue":"4","key":"974_CR17","doi-asserted-by":"publisher","first-page":"e36039","DOI":"10.1371\/journal.pone.0036039","volume":"7","author":"SR Schwartz","year":"2012","unstructured":"Schwartz SR, Rees H, Mehta S, et al. High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa. PLoS One. 2012;7(4):e36039.","journal-title":"PLoS One."},{"issue":"9","key":"974_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJMoa1905230","volume":"381","author":"R Zash","year":"2019","unstructured":"Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381(9):827\u201340.","journal-title":"N Engl J Med."},{"unstructured":"WHO. Update of recommendations on first- and second-line antiretroviral regimes. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325892\/WHO-CDS-HIV-19.15-eng.pdf?ua=1. Accessed 24 Sept 2019.","key":"974_CR19"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00974-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00974-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00974-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:27:49Z","timestamp":1631579269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00974-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00974-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"14 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no funding obtained for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mohammed Lamorde reports grants and non-financial support from ViiV, grants and personal fees from Mylan, and grants from Janssen Pharmaceuticals, outside the submitted work. Eva Agnes Odongpiny Laker, Arnold Arinaitwe, Noela Owarwo, Annet Onzia, Benson Nasasira, Abdullah Wailagala, Ivan Kalule, Godwin Anguzu, Agnes Kiragga, Kay Seden, Isaac Lwanga, Barbara Castelnuovo, and Rachel Musomba have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Analysis and publication of data obtained from the Infectious Diseases Institute Adult Clinic are approved and annually renewed by the School of Medicine Research and Ethics Committee, Makerere University Medical School (reference no. 2009-120) and the Uganda National Council for Science and Technology. All information is analyzed after removing unique personal identifiers.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients provided written or oral consent to participate in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"EL had final responsibility for the decision to publish. AA, NO, OA, NB, WA, AG, KS, RM, AG, IL, RM, BC, and ML all contributed to the design, data analysis, and interpretation of results. AG and AK were responsible for data extraction from the clinic database. EL, AA, NO, OA, NB, WA, KS, RM, AG, IL, RM, BC, and ML contributed to the drafting of the manuscript, reviewed the paper for substantial intellectual content, and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}